The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...

Pfizer CEO Dr. Albert Bourla was loudly booed during a White House Black History Month event where he was introduced by President Trump.

HHS secretary RFK Jr. said that he would “shut the revolving door to reestablish public trust” in the department.

Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's ...

Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, ...

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Greek-American Pfizer CEO Dr Albert Bourla faced an unwelcoming reception at the White House during an event celebrating ...